Mechanistically, miR-182 exerts this oncogenic role in CRC by targeting DAB2IP mRNA and activating the Wnt/β- catenin and PI3K/Akt/mTOR pathways [78]. This evidence concerns the gene MTOR and colorectal carcinoma.